- Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Precidian ETFs Trust - GSK plc ADRhedged(GSKH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GSKH
11/20/2026: GSKH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Precidian ETFs Trust - GSK plc ADRhedged (GSKH) provides targeted exposure to the equity performance of GSK plc while neutralizing currency fluctuations between local currencies and the U.S. dollar using derivative overlays. Its main strengths include a low expense ratio of 0.19% and precise currency risk management for US holders. The primary use case is tactical, single-stock international allocation within the healthcare sector. Key risks involve high single-stock concentration and modest trading liquidity. It best suits tactical investors seeking focused pharmaceutical exposure while keeping a close eye on execution spreads and underlying corporate developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | GSK is a mature pharmaceutical firm rather than a high-growth technology or biotech disruptor. |
| Momentum investor | Strong fit while signal remains positive | Technical trend-following strategies can utilize GSKH when the underlying pharmaceutical stock shows sustained upward momentum. |
| Value investor | Strong fit | The underlying asset trades at sensible valuation multiples typical of established global pharmaceutical leaders. |
| Dividend/Income investor | Strong fit | The fund provides exposure to GSK's stable dividend-paying profile adjusted for US holders. |
| Low-risk investor | Mixed fit | While currency-hedged, the fund remains heavily concentrated in a single corporate equity, carrying single-stock risk. |
Investor Profile
Ideal Investor Profile
Tactical investors or retail traders looking for concentrated exposure to GSK plc while specifically avoiding British pound/USD exchange rate exposure.
Suitability
Best suited for tactical allocations or focused satellite positions rather than core passive index-following portfolios.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | Medium | Although currency fluctuations are hedged, equity price swings inherent to a single pharmaceutical stock still affect returns. |
| Market risk | Medium / high | Broad equity market corrections and healthcare sector pressures can pull down the fund's value. |
| Concentration | High | The portfolio is essentially tied to a single underlying company (GSK plc), lacking stock diversification. |
| Tracking/expense | Low | A low expense ratio of 0.19% and effective swap mechanisms keep tracking error manageable. |
| Liquidity | Medium / high | Low assets under management and light daily trading volumes can result in wider execution spreads. |
| Business/sector quality | Medium | GSK is a stable global pharma enterprise, but faces ongoing patent cliffs, litigation, and drug pipeline execution risks. |
Sector & Industry Intelligence
This fund is not assigned to one sector.
Risk Analysis
Volatility
Historical volatility is tied closely to the equity price fluctuations of GSK plc, moderated by the elimination of currency swings via hedging instruments.
Market Risk
Carries high single-stock concentration risk and sector-specific vulnerabilities tied to the global pharmaceutical industry.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Single stock | GSK plc ADR (GSK) | 96.07 | Provides direct economic exposure to the core pharmaceutical business operations of GSK plc. |
| Cash/collateral | USD Cash and Equivalents | 3.57 | Holds liquidity buffers to support daily operations and derivative collateral obligations. |
| Derivatives | Other Assets Less Liabilities / Currency Hedging Contracts | 0.36 | Accounts for minor net assets and currency swap adjustments used to hedge exchange rate exposure. |
Price Behavior

Downtrend
The stock has experienced a sustained decline in price over recent periods.

Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type ETF | Historic Profit -11.76% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | ETF Returns Performance |

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

